Related Experiment Video

Updated: Aug 3, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Liver x receptors: potential novel targets in cardiovascular diseases

Dennis Bruemmer1, Ronald E Law

  • 1University of Kentucky, Department of Medicine, Division of Endocrinology and Molecular Medicine, Wethington Health Sciences Building, Lexington, 40536-0200, USA. Dennis.Bruemmer@uky.edu

Current Drug Targets. Cardiovascular & Haematological Disorders
|March 1, 2006
PubMed

Insights

Liver X Receptors (LXRs) are key targets for cardiovascular disease treatment. LXR agonists promote cholesterol removal, improve metabolism, reduce inflammation, and inhibit vascular cell growth, offering therapeutic potential.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Vascular Biology

Background:

  • Liver X Receptors (LXRs), including LXRalpha and LXRbeta, are nuclear hormone receptors.
  • LXRs play a critical role in regulating cholesterol homeostasis.
  • LXRs are emerging as significant pharmacological targets for cardiovascular diseases.

Purpose of the Study:

  • To review the functions of LXRs in metabolism and vascular biology.
  • To discuss the implications of LXRs as drug targets for cardiovascular conditions.

Main Methods:

  • Identification of natural and synthetic LXR ligands.
  • Generation and study of LXR-deficient mice.
  • Analysis of LXR-regulated genes involved in cholesterol metabolism and vascular function.

Main Results:

  • Synthetic LXR agonists enhance cholesterol efflux and reverse cholesterol transport.
  • LXR agonists improve glucose metabolism and inhibit inflammation.
  • LXR agonists suppress vascular smooth muscle cell proliferation, preventing atherosclerosis and neointima formation.

Conclusions:

  • LXRs are crucial regulators of cholesterol metabolism and vascular health.
  • LXR agonists demonstrate significant potential in preventing and treating cardiovascular diseases.
  • Targeting LXRs offers a promising therapeutic strategy for managing atherosclerosis and related conditions.

More Related Videos

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology12:36

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology

Published on: March 14, 2020

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...